Eptifibatide: The Snake-Venom Peptide That Blocks Platelet Clumping

Peptide drugs from venom

Eptifibatide is a synthetic cyclic heptapeptide, designed from a snake-venom disintegrin, that blocks the platelet receptor GPIIb/IIIa and was first approved in the United States in 1998. This article explains where the idea came from, what the large trials reported, and what the prescribing information says about its risks.

What is eptifibatide?

Eptifibatide is a cyclic heptapeptide, which means a seven-amino-acid peptide closed into a ring. Its prescribing information describes it as binding the platelet glycoprotein IIb/IIIa receptor and blocking the binding of fibrinogen and von Willebrand factor, which reversibly inhibits platelet aggregation. Because the effect is reversible, the label notes that platelet function recovers after the infusion stops. The same label gives a plasma elimination half-life of about 2.5 hours and lists 1998 as the year of initial US approval.

It is a hospital drug given by infusion in acute coronary syndromes and during coronary stenting, so it sits at the opposite end of the spectrum from the gut-restricted oral peptides covered in why peptides are not pills. Its backstory, though, is pure natural-product biology: the design started with a snake-venom protein.

From venom disintegrins to the KGD motif

Some snake venoms contain small proteins called disintegrins that carry an Arg-Gly-Asp (RGD) sequence. A 1993 Journal of Biological Chemistry paper from the company that developed eptifibatide describes RGD disintegrins as among the most potent inhibitors of adhesive-protein binding to GPIIb-IIIa, with a catch: RGD-containing antagonists are not integrin specific and also inhibit many other RGD-dependent integrins. One disintegrin, barbourin, has a conservative swap of lysine (K) for arginine (R) in that motif and is highly specific for GPIIb-IIIa. Eptifibatide is reported to derive from a disintegrin in the venom of the southeastern pygmy rattlesnake, and the authors used the barbourin information to design peptide antagonists with high GPIIb-IIIa specificity.

The same strategy, taking a venom-derived lead and refining it, appears in other drugs; see venom-derived peptide drugs and the cone-snail peptide ziconotide. Eptifibatide’s ring is held by a disulfide bridge, one of the structural features discussed in disulfide bonds in peptides and cyclic peptides and macrocyclization.

How eptifibatide is studied to work

Platelets stick together when GPIIb/IIIa on their surfaces is bridged by fibrinogen. By occupying the receptor, eptifibatide keeps fibrinogen and von Willebrand factor from linking platelets, which is why researchers describe it as acting on the final common step of aggregation rather than on any one upstream trigger. Since it is a peptide that must be infused, its short half-life is a feature: the effect fades within hours of stopping, which suits procedures where bleeding risk has to be managed.

What the eptifibatide trials reported

Two large trials anchor the evidence. PURSUIT enrolled 10,948 patients with acute coronary syndromes without persistent ST-segment elevation; the abstract reports a 1.5 percent absolute reduction in the composite of death or nonfatal myocardial infarction (14.2 percent versus 15.7 percent with placebo, P = 0.04), with benefit apparent by 96 hours and persisting through 30 days. The effect was consistent in most subgroups except women, and bleeding was more common with eptifibatide, although hemorrhagic stroke did not increase. ESPRIT randomized 2,064 patients undergoing coronary stenting to a double-bolus regimen or placebo on top of aspirin, heparin and a thienopyridine. It was stopped early for efficacy: the 48-hour composite fell from 10.5 percent to 6.6 percent (p = 0.0015) and the 30-day composite from 10.5 percent to 6.8 percent (p = 0.0034).

Safety information on the label

The label states that bleeding is the most common complication of eptifibatide therapy and reports acute profound thrombocytopenia, both immune and non-immune. It lists contraindications that include a bleeding diathesis or active abnormal bleeding within 30 days, severe uncontrolled hypertension, major surgery within 6 weeks, stroke within 30 days or any hemorrhagic stroke, use of another parenteral GPIIb/IIIa inhibitor, dialysis dependence and hypersensitivity. About half of the drug is cleared by the kidneys; the label reports roughly doubled steady-state concentrations when creatinine clearance is under 50 mL/min and recommends a reduced infusion rate, and it states that safety and efficacy have not been established in dialysis patients. This article gives no dosing guidance and is no substitute for the current label.

Research handling and unit context

Eptifibatide is supplied for clinical use as a sterile solution, not as a lyophilized research powder, so the reconstitution questions covered elsewhere on this site do not apply to it directly. General concentration arithmetic, if you want to see how mg, mL and mg/mL relate, is in the reconstitution calculator and the concentration converter; these are lab-math tools and not medical dosing instructions.

Frequently asked questions

Is eptifibatide a natural venom peptide?

No. It was designed using information from a venom disintegrin (barbourin). The drug itself is a synthetic cyclic heptapeptide.

Why does the KGD versus RGD difference matter?

According to the 1993 paper, RGD-based antagonists inhibit many integrins, while barbourin’s lysine-for-arginine change makes it highly specific for GPIIb-IIIa on platelets.

How long does its effect last?

The label gives a half-life of about 2.5 hours and says platelet function recovers after the infusion stops. Kidney function changes clearance.

What is its main risk?

The label identifies bleeding as the most common complication and also reports thrombocytopenia.

References

1. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
2. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT). Lancet 2000;356:2037-44.
3. Scarborough RM et al. Design of potent and specific integrin antagonists. J Biol Chem 1993;268:1066-73.
4. Integrilin (eptifibatide) prescribing information (label text, rev. 10/2019).
5. American College of Cardiology trial summary: PURSUIT.
6. Eptifibatide overview (secondary source; venom origin statement).

Informational only — not medical advice. This article is for educational purposes. It does not recommend, sell or instruct personal human use of any compound. Consult a qualified healthcare professional for any health decision. Content is intended for adults 21+. Verify scientific details against the primary sources cited.